Since January 24, @US_FDA has been reaching out to more than 180 drug manufacturers and reminding them of their applicable legal requirements to notify FDA of any anticipated supply disruptions as a result of the #coronavirus outbreak.
We have also asked them to evaluate their entire supply chain, including active pharmaceutical ingredients and other components manufactured in China. At this time, no firm has reported a shortage is anticipated for any drug due to #COVID19.
Additionally, FDA has identified about 20 drug products that solely source their active pharmaceutical ingredients or finished drug products from China. None of these firms has reported a shortage for any drug due to #coronavirus.
We will stay in contact with manufacturers so that we can assist them with any potential issues. Should FDA be made aware of any vulnerabilities or disruptions in the drug supply chain, we will work with manufacturers to quickly mitigate any shortages as a result of #COVID19.
Should a medical product shortage occur, FDA would determine how best to address it, taking into consideration a number of factors, including the public health risk associated with the shortage.
More information can be found on how FDA addresses drug shortages on our website: fda.gov/drugs/drug-sho…
